(Medical Xpress)—Researchers from the University of Dundee have discovered that measuring how active a gene is could predict which women with ovarian cancer will benefit from platinum-based chemotherapy drugs - a common ...
Sep 19, 2012
0
0
Researchers had previously reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based chemotherapy in untreated advanced nonsquamous non-small cell lung cancer patients. ...
Sep 8, 2019
0
4
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast ...
Apr 8, 2013
0
0
(HealthDay) -- For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, ...
May 31, 2012
0
0
(HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published ...
Aug 14, 2012
0
0
Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk of long-term side-effects, a new study reports. As many as 96% of men ...
Aug 16, 2013
0
0
In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of ...
Dec 13, 2013
1
0
A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.
Feb 12, 2019
0
0
Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from the randomized phase II GeparSixto clinical trial presented at ...
Dec 9, 2015
0
2
(HealthDay)—For children with high-risk group 3 medulloblastoma, therapy intensification with carboplatin improves event-free survival, according to a study published online July 22 in JAMA Oncology.
Jul 23, 2021
0
1
